California v. AbbVie—Potential Limits in the Marketing of High-Risk Drugs
By Maria C. Nunez, Ashley N. Mays-Williams, Ph. D., and Julia M. Kolibachuk
On Sept. 18, 2018, the State of California (henceforth, referred to as the ‘‘State’’) sued AbbVie Inc. (‘‘AbbVie’’) and 25 undisclosed health-care providers (collectively, ‘‘Defendants’’) for allegedly violating California’s Insurance Frauds Prevention Act. (D.I. 1 (C.A. RG18893169), Complaint.) The State’s complaint supersedes an initial complaint filed by Lazaro Suarez, a registered nurse whose services were contracted by AbbVie from approximately March 2013 to October 2014 as part of an alleged kickback scheme.